Research programme: fusion proteins - Symphogen

Drug Profile

Research programme: fusion proteins - Symphogen

Alternative Names: RB 200; RBLX-200; RBLX-242; Sym 011

Latest Information Update: 10 May 2013

Price : $50

At a glance

  • Originator Receptor BioLogix
  • Developer Symphogen
  • Class Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Epidermal growth factor receptor modulators; ERBB-3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Mar 2011 Preclinical trials in Cancer in Denmark (Parenteral)
  • 19 May 2010 This programme is still in active development
  • 30 Jan 2009 Symphogen acquires research programme from Receptor BioLogix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top